PARP inhibitor
Drug timelines are a Plus or Pro feature.
18 regulatory and trial events tracked for PARP inhibitor, covering 2009-05-15 to 2026-03-16. Get the full timeline:
Most recent: Clinical Trial Update: PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer [Phase 2, Phase 3]